Protein diet – is another name for the Kremlin diet and the Atkins diet. But, in a nutshell on this diet we will tell you straight to the page.

Protein diet is one of the most efficient and fastest ways to lose weight. The principle of this method lies in bringing about a kind of stress the body by repeatedly increasing protein and a significant reduction of carbohydrates in the diet. In the human body that respects the principle of such power, a sharp evolution of metabolism – the shortfall in the main “fuel” – carbohydrates, leads to burning extra fat reserves. Thus, two weeks of compliance protein diet can lose weight by 4-8 kg.

Being a very effective, this technique, however, far from unsafe conditions in non-compliance with its rules. When excessive overabundance of body protein (diet more than the period) and long-term shortage of carbohydrate may suffer skin and hair, as well as fatigue and insomnia appear. Therefore, even with a significant effect of diet protein weight loss can be practiced only once in 2-3 years.

Protein diet is very popular among athletes and bodybuilders as a protein, which is in excessive amounts in the body helps to quickly build muscle mass.

The most important condition for the protein diet – do not eat sweet and starchy foods containing large amounts of carbohydrate. It is also necessary to eliminate or reduce the consumption of all energy-dense foods. Vodka for a zero carbohydrate diet consumed by the Kremlin’s possible, but it is not necessary because Alcohol slows down your metabolism.

To ease problems posed by diet, you can use special tables or analyzer recipes on the website – these services help you learn how much carbohydrate, protein, fat and calories contained in foods. For the preparation of the daily diet may ask the dietitian in the “doctor’s advice.” Properly composed specialist diet will be high, and, moreover, never do any harm.

As we continue to move forward in the area of clinical pharmacology
aspects of drug development, we are faced with worldwide pharmaceutical
companies, an explosion of data, and increased knowledge of the
importance of optimal drug administration and the consequences of less
than optimal drug use. In this context, computer-based systems increasingly
provide an essential means of communication, as well as an effective tool for
modeling and simulation. From the internet to personal information
managers and Pocket PCs, we are nearly always close to a source of drug
information. An increasingly common utterance is that there is so much
information available but there are also increasing difficulties in sorting
through this avalanche of information to find what is useful and thereby
translating information into useful knowledge. But, there can be no
question that computer-based information will continue to expand and
progress as one of the most important means of communication and sources
of information.
Clinical trial simulation [41] has matured to a point where all available
information about a drug under development can be used efficiently to
promote more rapid drug development. The entire process of drug
development has been estimated to take up to 12 years and cost upwards of
$350 million. About one-third of this cost and half the time is spent on
clinical development. Simulation techniques can provide valuable
information related to optimal dosing schedule, expected range of response,
effects of changes in exclusion criteria on expected outcome, optimal
frequency to measure response, and the impact of compliance.
Effective labeling has become an important topic, as large amounts of
information become available for newly approved drugs. Drug interactions
studied for a new drug have implications for the other drugs involved in the
interactions and keeping labeling up to date for all drugs is a difficult task.
As difficult is the task of healthcare providers being aware of all patient
situations where dose adjustment may be appropriate, related to age,
gender, race, renal or hepatic function, or drug interactions. FDA has
proposed a new labeling format [42] in the effort to present important
dosing and other safety information more clearly and obviously.
The use of population pharmacokinetics [30] allows for the study of
differences in safety and efficacy among population subgroups. This
approach, which involves obtaining plasma samples from patients
participating in clinical studies, can permit the identification of important
factors, such as age, gender, weight, renal function, hepatic function, and
concomitant medications which can affect the safe and effective use of a
drug.
A topic of interest and considerable discussion recently is the Global
Clinical Trial. Clinical trials conducted in the United States. Europe, or
Japan often need some type of bridging study to allow the existing clinical
data to be used in the approval process in a different region of the world. A
Global Clinical Trial would include patients from the three ICH regions and
might allow the results of the trial to be directly applicable for approval in
all three regions and thereby speed worldwide drug approval.
Risk management is a frequently heard term in the current and future era
of a complex healthcare environment, with many potent new drugs being
approved, and an emerging global market. The FDAs Task Force on Risk
Management [43] has recommended that a new framework for risk
management activities is needed. The current system, which involves not
only the FDA but also pharmaceutical manufacturers, healthcare
practitioners, and patients, is more fragmented rather than part of an
integrated systems effort. One important recommendation relates to risk
confrontation, which involves community-based problem solving and
involves all stakeholders in the decision-making process. Regarding postmarketing
surveillance and risk assessment, it has been suggested that new
approaches be considered such as increasing reliance on computer-based,
perhaps global, health information databases, as well as gathering data
from identified sentinel facilities where staff are trained to recognize rapidly,
and report accurately, adverse reactions.
In conclusion, one of the most striking developments in this area over
the past 30 years has been the change from independent clinical studies
conducted in patients with the goal of determining safety and efficacy, and
independent pharmacokinetic studies conducted in healthy subjects, to the
current situation where these studies are viewed together. Over the years,
these two sources of data have become increasingly associated and utilized
together in numerous approaches to efficient drug development. By
obtaining some additional plasma samples from patients in clinical
studies, all studies in humans can be viewed as a continuum and a more
complete evaluation of a drug can be obtained. By the integration of all
available drug development data, dose can be better optimized for each
patient, thereby minimizing adverse reactions and promoting effective
treatment of diseases.

In 1991, a Workshop was held to discuss current thinking related to the
rational integration of pharmacokinetics, pharmacodynamics, and
toxicokinetics [35]. This was an important milestone along the path of
closer relationships between clinical data and pharmacokinetic data.
In CDER, a reorganization establishing the Office of Clinical
Pharmacology and Biopharmaceutics in conjunction with increased
resources related to User Fees, promoted communication among medical
reviewers and clinical pharmacology reviewers. Co-location of these
reviewers provided for increased discussions, data sharing, and
consultations.
The importance of the relationship of changes in pharmacokinetics to
drug safety and efficacy is a continuing topic of much discussion. One
related area is drug interactions, which sometimes are extremely
important.
The interaction of fluorouracil and sorivudine, which caused a
number of deaths in Japan [36] in the 1990s, served as an important
reminder of the potential consequences of drug-drug interactions.
Sorivudine was withdrawn in Japan after 15 patients who were
prescribed both sorivudine and fluorouracil died. They had developed
aplastic anemia, after taking sorivudine with fluorouracil. Knowing the
situation that had occurred in Japan, sorivudine was not approved in the
United States because of this potentially fatal drug interaction and the
fact that alternative drugs to sorivudine were available, without the
serious drug interaction potential.
Serious interactions between mibefridil and certain cholesterol lowering
“statin” drugs resulted in the removal of mibefridil from the market.
Mibefradil is a potent inhibitor of the metabolism of lovastatin and
simvastatin and if either of these drugs is taken together with mibefridil,
they can cause potentially life-threatening rhabdomyolysis related to much
higher exposure to the statin drug due to inhibited metabolism caused by
mibefridil [37].
In response to the significance of drug interactions, Guidances for the
study of potential drug interactions, both in vitro [38] and in vivo [39], are
available from FDA. Study continues on establishing in vitro/in vivo
correlations for metabolically related drug interactions, in order to increase
the predictability of in vitro drug interaction data.
An important new law went into effect in 1997. The Food and Drug
Administration Modernization Act (FDAMA) [40] contained many new
provisions including a section describing the number of required clinical
investigations needed for approval. “If the Secretary determines, based on
relevant science, that data from one adequate and well-controlled clinical
investigation and confirmatory evidence (obtained prior to or after such
investigation) are sufficient to establish effectiveness, the Secretary may
consider such data and evidence to constitute substantial evidence….” The
confirmatory evidence described can be obtained from earlier clinical trials,
pharmacokinetic data, or other appropriate scientific data. This indicates
further reliance on pharmacokinetic data in conjunction with clinical
studies in the overall development of a new drug.

With the ability to conduct pharmacokinetic studies well established,
attention advanced to additional applications. One such area was the study
of various sub-populations, including the elderly, males compared to
females and possible racial differences in pharmacokinetics. These aspects
have continued to be emphasized and currently, it is expected that all NBAs
will include analysis of data related to age, gender, and race.
CDER has used numerous methods to move forward the science of drug
regulation. This includes involvement in Workshops to discuss current drug
regulatory issues and the development of Guidances to put forward
recommendations to sponsors as to how to proceed in many areas including
clinical pharmacology studies. These Guidances include both
CDER-developed documents [26] and ICH Guidelines [27].
The importance of age-related differences in response to drugs is
discussed in a CDER Guidance [28]. A pharmacokinetic screen [29] is
recommended, consisting of obtaining blood samples from patients in Phase
II and Phase III clinical investigations. This is a means of identifying
subgroups of patients, such as the elderly, in whom the drug may have
unusual pharmacokinetic characteristics. Procedures such as the
pharmacokinetic screen have evolved into current methods of population
pharmacokinetics [30].
An example, from about 20 years ago, of a drug which proved to have
serious toxicity among some elderly patients was benoxaprofen, a nonsteroidal
anti-inflammatory drug, used to treat arthritis. It was
promoted as perhaps capable of “arresting the disease process” in
rheumatoid arthritis. While it was certainly effective for labeled
indications, for certain elderly patients it was associated with fatal
cholestatic jaundice among other serious adverse reactions. If the
pharmacokinetics of benoxaprofen had been studied in the elderly, it is
possible that a dose adjustment for elderly could have been
recommended and withdrawal of benoxaprofen from the market, which
occurred in 1983, might have been avoided [31].
While for most drugs, males and females can safely receive the same dose,
for a few drugs, differences in pharmacokinetics related to gender can be
important. In 1993, the Guideline for the Study and Evaluation of Gender
Differences in the Clinical Evaluation of Drugs [32] was published. This
recommended inclusion of patients of both genders in drug development,
assessment of clinical data by gender, assessment of potential
pharmacokinetic differences between genders, and the conduct of specific
additional studies in women, when appropriate.
Patients with impaired renal or hepatic function are also important subpopulations.
Consideration of the need for dosage adjustment in
situations of renal or hepatic impairment has received considerable
attention. Guidances [33, 34] addressing these topics are available from
FDA.

The modern era of drug development related to clinical pharmacology
studies may be thought to have begun in the 1970s. A key component was
the development of bioanalytical methods needed to accurately detect
plasma concentrations of administered drugs. This aspect has continued to
improve until it is now possible to measure plasma levels for nearly every
drug under development. This is an important factor in the study of the
relationships of dose, exposure, and effect.
An important regulatory milestone was the creation of the distinct Human
Pharmacokinetics and Bioavailability Section of NDAs [24]. This established
a section in each NDA in which are contained all clinical pharmacology and
biopharmaceutics studies. Prior to what is called the NDA rewrite, NDAs
were not very consistent in content, and information to be included was not
very precisely defined or well organized. When this Format and Content
Guideline was first introduced in 1987, the types of studies were identified as:
• Pilot or background studies carried out in a small number of
subjects as a preliminary assessment of ADME.
• BA/BE studies.
• Pharmacokinetic studies.
• Other in vivo studies such as those using pharmacological or
clinical endpoints in humans or animals.
• In vitro studies such as dissolution and protein binding studies.
While the original focus was on in vivo studies in healthy subjects, this has
expanded to include plasma sampling in patients as part of population
pharmacokinetic studies, exposure response studies and pharmacokinetic/
pharmacodynamic studies.
There are numerous types of clinical pharmacology studies conducted
during the development of a new drug. These include both studies on
healthy subjects without the disease intended for treatment (Phase I) and
studies involving patients (Phase II and III).
Studies in healthy subjects primarily focus on safety aspects of the drug,
in establishing dose-toxicity relationships. These studies also investigate the
pharmacokinetics for the drug under development, dose proportionality,
absolute bioavailability, mass balance, effect of food, different formulations,
as well as special populations.
Studies conducted in patients primarily relate to establishing efficacy and
dose/response. In addition, optimal dosing interval, effect of severity of
disease, tolerance, and adverse reactions are determined.
One significant example from this era involved a once-a-day extended
release theophylline product which was shown to have a significant change
in bioavailability when administered with a high fat meal. This important
safety information resulted in the following precaution being added to the
product’s labeling:
Drug/Food Interactions Taking (this product) less than one hour before a highfat-
content meal, such as 8 oz whole milk, 2 fried eggs, 2 bacon strips, 2 oz
hashed brown potatoes, and 2 slices of buttered toast (about 985 calories,
including approximately 71 g of fat) may result in a significant increase in peak
serum level and in the extent of absorption of theophylline as compared to
administration in the fasted state. In some cases (especially with doses of 900
mg or more taken less than one hour before a high-fat-content meal) serum
theophylline levels may exceed the 20mcg/mL level, above which theophylline
toxicity is more likely to occur.
A CDER Guidance [25] is available which describes current
recommendations related to food effect studies and labeling based upon
the results of such studies. Drug administration relative to meals is
sometimes of great importance. The labeling for atovaqone serves to
illustrate a situation where drug must be taken with food for optimal
efficacy:
Failure to administer (atovaquone) with meals may result in lower plasma
atovaquone concentrations and may limit response to therapy.

An analysis of outcomes of applications in the Central Procedure from 1995
to 1999, published by the EMEA [21], has shown 72% (97/135) positive
outcomes, i.e., drug approvals. For applications with a negative outcome,
methodological concerns over study design, choice of endpoint, comparator,
and selected population were raised more frequently than over those with a
positive outcome. FDA had authorized 13 (34%) of the 38 applications that
had a negative outcome in the EU. This may be explained by a different
attitude toward data requirements e.g., requirements for controlled data, by
the availability to FDA of additional regulatory tools, e.g., conditional
approvals, and by the limited use of EMEA scientific advice (11%) prior to
submission [22].
It is expected that the Reform of EU Pharmaceutical Legislation,
proposed in 2001, will influence the regulatory environment
significantly

From the same consultation in Europe, comparative observations upon the
regulatory frameworks in the EU and United States have revealed a
perception that the EU is taking a more risk-adverse approach to assessment
as compared with the FDA’s policy of risk management. Specific instances
would exist where products were removed, or threatened with removal,
from the EU market because of perceived safety concerns, while the same
products were dealt within the United States by the imposition of specific
warnings in the label [21]. Comments were made about a similar level of
conservatism in the EU in the approach to the review of products in
specialist areas such as oncology and a greater willingness to embrace new
therapies in the United States

In 2000, an extensive consultation [21] was carried out on behalf of the
European Commission to review the operation of the new European System
since 1995. It has revealed that there is a broad level of satisfaction about
the system from ministries, patient and professional associations, regulatory
authorities, and industry, although improvements can be made and new
challenges exist.
There is a general feeling that the system has contributed to the creation
of a harmonized EU market for medicinal products and that it provides a
strong foundation for an efficient regulatory environment. There is also a
general perception that assessment of products to date has provided a high
degree of protection to the public health. This is despite the fact that there
have been withdrawals from the market of products already authorized.
This is considered consistent with increasingly effective pharmacovigilance
procedures and the bias toward products developed on the leading edge of
science.

The European System offers two routes for granting authorizations. A
company can or must, depending on the type of product, seek centralized
approval, which means an authorization valid for the whole EU. The
centralized procedure is compulsory for biotechnology products and
optional for innovative conventional products. In this case the application is
dealt with administratively by the EMEA. Independent evaluations are
conducted by two selected members of the European scientific committee
(named CPMP, Committee for Proprietary Medicinal Products).
Multidisciplinary teams, coordinated by the selected members, perform
those evaluations and discuss their conclusions with the other members. The
European Commission makes final decisions after the CPMP has expressed
an opinion following its scientific debate.
For innovative conventional products a company can instead choose the
route based on mutual recognition of national decisions. The European
System affords many advantages. New medicines come to market faster,
which of course benefits patients and industry. Also, by utilizing the
collective competence of several national drug authorities, the quality and
objectivity of evaluations can be improved, duplication of work is avoided,
and harmonized opinions and labeling throughout the EU becomes
available.
An important part of this European-oriented work also revolves around
developing new standards and requirements in the face of rapid scientific
discoveries and development of new medicines. The intended end result is to
promote public health and free circulation of medicines

The standards of safety expected for an agent which may be lifesaving and
one which relieves minor symptoms should not be the same. Perceptions
on the appropriate balance of risk and benefit however vary widely,
including nationally. Based on evidence of efficacy, which may be
uncertain, together with limited safety data, licensing decisions may need
to be made on as much a judgmental as a scientific basis [5]. While formal
analysis of risk and benefit for a particular drug can be carried out,
comparative risk assessment with similar drugs is also considered useful
(see next paragraph).
Efficacy and safety have traditionally been the most important
influential bases to make decisions. In the future, priorities may also be
more influenced by costs and expected benefits of drugs on the market. At
present pharmacoeconomic data are required for requesting
reimbursement in countries such as Netherlands, United Kingdom,
Denmark, Finland, Norway, and Portugal. In the future more information
regarding the efficiency of the drug as compared to available drugs may be
needed, thus magnifying the social value of the resources invested on drug
expenditure
At the end, drug development should contribute to the use of the most
appropriate drug to the right patient in an optimal dosage schedule with the
right information and at a reasonable cost.